Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) CEO Chandler Robinson sold 29,056 shares of the business’s stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $88.00, for a total value of $2,556,928.00. Following the sale, the chief executive officer owned 99,267 shares of the company’s stock, […]

Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) CEO Abraham Ceesay sold 2,210 shares of the business’s stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $39.17, for a total transaction of $86,565.70. Following the sale, the chief executive officer directly owned 456,767 shares in the company, […]

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total value of $684,500.00. Following the completion of the sale, the chief executive officer owned 235,244 shares of the […]